• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Biosimilars Have Unfulfilled Potential to Expand Earlier Biologic Use

Commentary
Article

In this Q&A, James D. Chambers, PhD, MPharm, MSc, discusses the promise and progress of biosimilars in expanding US access to biologics.

Biosimilars have gained significant acceptance among US payers in recent years, but their cost savings have not yet led to broader access to biologics earlier in the treatment pathway, according to James D. Chambers, PhD, MPharm, MSc, associate professor at the Center for the Evaluation of Value and Risk in Health at Tufts Medicine. Chambers was a panelist during the “Repositioning of Biosimilars: How Can the US Optimize Biosimilar Utilization to Improve Patient Health and Lower Total Cost of Care?” session at the Academy of Managed Care Pharmacy Nexus 2026 meeting, held in San Diego, California.

At the meeting, he spoke with The American Journal of Managed Care® (AJMC®), the sister publication of the Center for Biosimilars®, about what international biosimilar models can teach the US, how differences between health plans affect access to biologics, and how managed care pharmacists can lead the review of evidence when a biologic loses exclusivity.

This transcript has been lightly edited for clarity.

Dr James Chambers | Image Credit: Tufts Medicine

In this Q&A, James D. Chambers, PhD, MPharm, MSc, discusses the promise and progress of biosimilars in expanding US access to biologics. | Image Credit: Tufts Medicine

AJMC: Biosimilars are often described as a gateway to more affordable, equitable biologic treatment. Where has that promise held up in the US, and where has it fallen short?

Chambers: The US has lagged behind other jurisdictions in this a little bit, notably Canada and Europe. As I showed in my talk today, though, the US is gaining ground here, and I think biosimilars are much more accepted now than they were before.

In 2017, for instance, we found that 55% of policies for the biologics, so the originator product and biosimilars, required that the patient first fail the originator product before they could access the biosimilar. In 2025, that was down to only 6%, and 94% of the time a biosimilar was available as the preferred product. So, at least through the payer lens, we’ve seen great advancement in how they prioritize biosimilars over time.

Now, I think there’s still room for improvement. One thing we talked about on our panel was: could biosimilars encourage a repositioning of biologics in the treatment pathway? An example I gave was for ulcerative colitis. In the clinical guidelines that are out there, the American College of Gastroenterology recommends biologics as first-line treatments, or that they be considered for first-line treatment. But we find that payers typically require patients to step through conservative therapy first before they can access the biologic.

The fact that biosimilars drive down the price of these biologics so much, I think, offers opportunities to align payer policies with clinical guidelines. So, biosimilars offer great potential. I don’t think that we’re there yet in terms of achieving that potential.

AJMC: Could you elaborate on the most successful examples of biosimilar repositioning and what they have shown about patient access, clinical outcomes, and total cost of care?

Chambers: I was involved in a report at the Office of Health Economics in London, and they did a really nice paper on this, trying to look across regions. One good example that they included was bevacizumab for metastatic colorectal cancer in the UK, where the National Institute for Health and Care Excellence had rejected or chosen not to recommend the use of bevacizumab for metastatic colorectal cancer 3 times. But then, when the biosimilar was introduced for bevacizumab, they adjusted the decision, and the report went on to estimate quite large health benefits according to that.

I think there are opportunities there, but this repositioning is nascent. It’s new, and I think that’s where, hopefully, we see changes and where biosimilars really begin to benefit patients in the future.

AJMC: Which elements of international biosimilar models could be adapted to the US market, and what challenges might limit their implementation?

Chambers: The US is a fragmented system. It’s the differing incentives between the payer, pharmacy benefit manager, and the provider. The fragmented nature of it means we didn’t get the same immediate sort of embracing of biosimilars that we saw in other countries.

In other countries, I think it is typically a centralized system, which really helps. I think procurement encourages competition amongst biosimilars in other countries, which also really helps. I think just in general, better communication and education in the early days for biosimilars in those other regions also helped where maybe the US lagged behind a little bit.

AJMC: How does alignment or misalignment among payer coverage and reimbursement policies influence biosimilar utilization, and what policy changes could help improve access?

Chambers: Within the Specialty Drug Evidence and Coverage database, which is a database developed at Tufts Medicine that tracks how the largest payers cover specialty drugs, one of the trends we find across all of our analyses is variation. I talked about that a little bit today during my session, in that we see different plans, with variation amongst plans with respect to how often they make the biologic the preferred therapy; we really find variation important.

So, some plans never made the biologic the preferred therapy, and this is for ulcerative colitis, I should clarify, and had patients step through conservative treatment, meaning corticosteroids largely for ulcerative colitis. But other plans made the biologic the first-line treatment, whether it be the biosimilar or the originator. That variation has implications for patients, because it means they’ve got differing access to biologics, and also for providers, because providers then have to tailor their treatment choice not only to the patient’s clinical presentation but also to the patient’s insurance coverage.

How do we improve that? I mean, it’s a good question. I think transparency is something we always improve on: how those decisions are made. But given the system we have over here with rebates and different insurers negotiating separately with manufacturers, I think that variation’s maybe here to stay, not just in the biosimilar space but also in how payers cover a variety of different specialty therapies.

AJMC: What would a structured process for reassessing a biologic after loss of exclusivity look like, and how can managed care pharmacists contribute to evidence evaluation and formulary decision-making?

Chambers: I think pharmacists are very well positioned to do this. I think whenever a biologic loses exclusivity, hopefully in the future it won’t just trigger a contracting event, but it’ll trigger a broader reassessment of the evidence, including what the guidelines are telling us to do. The economics of treating the disease with biologics and also existing utilization management and access requirements.

I hope in the future we’ll see a greater sort of more holistic assessment of these things. As I said, pharmacists are perfectly placed to do this, to ensure that we’re really providing patients with adequate and appropriate access to biologics. Hopefully, that is in better alignment with some of the clinical guidelines out there.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Dr James Chambers
Juliana M. Reed, MS
© 2026 MJH Life Sciences

All rights reserved.